2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
Cardiovascular disease and COPD: dangerous liaisons?
Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD)
frequently occur together and their coexistence is associated with worse outcomes than …
frequently occur together and their coexistence is associated with worse outcomes than …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
[HTML][HTML] Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD
KF Rabe, FJ Martinez, GT Ferguson… - … England Journal of …, 2020 - Mass Medical Soc
Background Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting
muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronic obstructive …
muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronic obstructive …
[HTML][HTML] Once-daily single-inhaler triple versus dual therapy in patients with COPD
DA Lipson, F Barnhart, N Brealey… - … England Journal of …, 2018 - Mass Medical Soc
Background The benefits of triple therapy for chronic obstructive pulmonary disease (COPD)
with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long …
with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long …
Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary
CF Vogelmeier, GJ Criner, FJ Martinez… - American journal of …, 2017 - atsjournals.org
This Executive Summary of the Global Strategy for the Diagnosis, Management, and
Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 …
Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 …
Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind …
FJ Martinez, KF Rabe, GT Ferguson… - American Journal of …, 2021 - atsjournals.org
Rationale: In the phase III, 52-week ETHOS (Efficacy and Safety of Triple Therapy in
Obstructive Lung Disease) trial in chronic obstructive pulmonary disease (COPD) …
Obstructive Lung Disease) trial in chronic obstructive pulmonary disease (COPD) …
Treatment trials in young patients with chronic obstructive pulmonary disease and pre–chronic obstructive pulmonary disease patients: time to move forward
Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and
cumulative gene–environment interactions over a lifetime. The evolving understanding of …
cumulative gene–environment interactions over a lifetime. The evolving understanding of …
Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease
DA Lipson, C Crim, GJ Criner, NC Day… - American journal of …, 2020 - atsjournals.org
Rationale: The IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease
Treatment) trial demonstrated a significant reduction in all-cause mortality (ACM) risk with …
Treatment) trial demonstrated a significant reduction in all-cause mortality (ACM) risk with …
Defining the relationship between COPD and CVD: what are the implications for clinical practice?
Cardiovascular diseases (CVDs) are arguably the most important comorbidities in chronic
obstructive pulmonary disease (COPD). CVDs are common in people with COPD, and their …
obstructive pulmonary disease (COPD). CVDs are common in people with COPD, and their …